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Abstract 
 
Introduction: Endometriosis is a hormone-dependent benign chronic disease that requires a 
chronic medical therapy. Although currently available drugs are efficacious in treating 
endometriosis-related pain, some women experience partial or no improvement. Moreover, the 
recurrence of symptoms is expected after discontinuation of the therapies. Currently, new drugs are 
under intense clinical investigation for the treatment of endometriosis. 
 
Areas covered: This review aims to offer the reader a complete and updated overview on new 
investigational drugs and early molecular targets for the treatment of endometriosis. The authors 
describe the pre-clinical and clinical development of these agents.   
 
Expert opinion: Among the drugs under investigation, late clinical trials on gonadotropin-releasing 
hormone antagonists (GnRH-ant) showed the most promising results for the treatment of 
endometriosis. Aromatase inhibitors (AIs) are efficacious in treating endometriosis related pain 
symptoms but they cause significant adverse effects that limit their long-term use. New targets have 
been identified to produce drugs for the treatment of endometriosis, but the majority of these new 
compounds have only been investigated in laboratory studies or early clinical trials. Thus, further 
clinical research is required in order to elucidate their efficacy and safety in human. 
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1.0 Introduction 
Endometriosis is a chronic hormonal benign disease with affects 1-5% of women of reproductive 
age, and it is defined as the presence of endometrial glands and stroma outside the uterus (1-3). 
Endometriosis includes three clinically distinct forms: peritoneal implants, ovarian endometriomas 
(OEs) and deep infiltrating endometriosis (DIE). This disease causes pain symptoms (such as 
dyspareunia, dysmenorrhea, non-menstrual pelvic pain and dyschezia) and infertility in women of 
reproductive age. As endometriosis is an estrogen-dependent disease, patient’s symptoms are 
influenced by the cyclical fluctuations of ovarian hormones physiologically occurring in fertile 
women. Pain symptoms usually regress after menopause; however, the disease can be diagnosed in 
postmenopausal women undergoing surgery (4). Despite extensive research, the understanding of 
the pathogenesis of endometriosis remains incomplete (2). Transvaginal ultrasonography is the gold 
standard technique for the diagnosis of deep endometriosis (5) and ovarian endometriomas (6); 
magnetic resonance imaging (MRI) may be used when the gynecologists have no experience in the 
ultrasonographic diagnosis of endometriosis or when the findings of ultrasonography are unclear. 
Surgery and the histological examination are the gold standard for the definitive diagnosis of 
endometriosis (7). 
The treatment of endometriosis involves conservative or radical surgery, or medical therapies. 
Although surgery improves endometriosis-associated pain, quality of life and sexual function (8), it 
can be technically demanding and it carries the risks of visceral, vascular and neurological 
complications. Medical therapy often represents the first-line management for women with 
endometriosis, aiming to ameliorate pain symptoms and to prevent post-surgical disease recurrence. 
The choice of the therapy is based on several factors, such as age of the patients, intensity and 
characteristics of pain, preference of the patients, desire to conceive and presence of comorbidities 
(such as migraine) (9). The medical management of patients with endometriosis is challenging due 
to the need of a tolerable chronic regimen, the partial relief of symptoms that often is obtained with 
current medical therapies and to the fact that pain recurs after the discontinuation of the hormonal 
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treatment. Traditionally combined oral contraceptives (COCs) have been the first-line treatment for 
patients with endometriosis, but currently progestins are increasingly and successfully employed as 
monotherapy, being efficacious and well tolerated for long-period of time (10). These hormonal 
compounds are efficacious in controlling symptoms in about two-third of women. Second-line 
therapy is represented by gonadotropin releasing hormone agonists (GnRH-as), which have a less 
favorable tolerability profile (9). Thus, research is focusing on finding new alternative therapies for 
the treatment of to this minor percentage of patients resistant to common first-line hormonal 
treatments. This review aims to offer the reader a complete overview on last drug development and 
early investigated targets for the treatment of endometriosis.  
 
2.0 Current medical therapy of endometriosis  
Nonsteroidal anti-inflammatory drugs (NSAIDs) are largely used for the treatment of 
endometriosis; however, there is a lack of high-quality evidence supporting their efficacy in 
managing pain caused by endometriosis. Furthermore, no evidence shows whether any individual 
NSAID is more effective than another (11). Finally, women taking NSAIDs must be aware that 
these drugs may cause unintended adverse effect (AEs). 
COCs and progestins are first-line therapies and they are often started empirically without a 
confirmed surgical diagnosis of endometriosis (12, 13). COCs act promoting a supraphysiologic 
levels of estrogen due to the high estrogenic activity of ethinyl estradiol (EE), thus causing a 
decrease of estradiol levels. This condition suppresses ovulation, improving symptoms of women 
affected (2). The continuous use of progestins as monotherapy inhibits ovarian steroidogenesis with 
subsequent anovulation and decrease of serum levels of endogenous ovarian steroids, causing 
decidualization of endometriotic implants. Moreover, progestins are able to locally inhibit 
inflammatory pathways and response, and cause apoptosis of ectopic endometriotic cells (14). 
Overall, these two hormonal medical options enable satisfactory long-term pain control in around 
two-thirds of symptomatic women (2). The imbalance of estrogen receptor and progesterone 
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receptor subtypes as well as adhesion molecules may contribute to the mechanisms involved in the 
resistance of this subpopulation refractory to these first-line hormonal therapies. As there are not 
biomarkers predictive for this resistance, a dynamic monitoring of response to these drugs is thus 
warranted in order to switch to other medical options or to discuss the most appropriate time for the 
surgical option (15).  
An accurate diagnostic workup is required prior to administering second-line therapies such as 
GnRH-as (16). These drugs suppress estrogen ovarian production through the down-regulation of 
gonadotropin-releasing hormone (GnRH) receptors at pituitary level, suppressing the production 
and release of gonadotropins. The hypoestrogenism and subsequent amenorrhea cause regression of 
endometriotic implants. GnRH-as, causing the initial stimulation of the hypothalamic-pituitary-
gonadal axis, may cause a surge in estrogen levels that is associated with a worsening of symptoms 
(flare-up effect). Anyway, it does not represent a major issue whether the treatment is started in the 
mid-luteal phase (17). However, GnRH-as are responsible of several AEs such as alteration of lipid 
profile, depression, flushes, urogenital atrophying and loss of bone mineral density (BMD). The 
intensity of these AEs can be decreased by administering “add-back” therapies with progestins, 
such as norethisterone acetate (NETA). Progestins as “add-back” therapy tend to be preferred to 
COCs since in these seconds the estrogenic activity of the dose of EE is too high relative to 
physiologic levels of E2 (17).  
 
3.0 Investigational treatments for endometriosis 
Endometriosis is a multifactor disease in which estrogens and progesterone play a fundamental role. 
The development and maintenance of endometriosis depend on the alteration of multiple cell 
mechanisms, such as the proliferation, apoptosis and invasion capacity. The formation of 
endometriotic lesions involves also the imbalance of tissue-adhesive properties, the activity of 
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matrix metalloproteinases and the triggering of an angiogenic response. Moreover, the presence of 
ectopic implants is associated with overproduction of prostaglandins, cytokines and chemokines (2). 
Understanding the complex mechanisms of this chronic hormonal disease paved the way to the 
improvement of currently existing treatment options and the investigation of novel targeted drugs 
(Figure 1). The following paragraphs will describe different classes of new investigational drugs for 
the treatment of endometriosis that are currently in pre-clinical and late and early clinical studies 
(Table 1).  
 
4.0 Hormonal therapies 
4.1 Gonadotropin releasing hormone antagonist 
GnRH is the hypothalamic hormone that induces pituitary secretion of follicle-stimulating hormone 
(FSH) and luteinizing hormone (LH). Gonadotropin-releasing hormone antagonists (GnRH-ant) act 
by binding to the same pituitary GnRH receptor, and, they suppress gonadotropin production. The 
induced hypoestrogenic state inhibits proliferation and invasion of ectopic endometrial cell. 
However, differently form GnRH-as, GnRH-ant maintain sufficient circulating estradiol (E2) levels 
to avoid vasomotor symptoms or loss of BMD. When starting the therapy, there is a further 
advantage of GnRH-ant over GnRH-as: they have an immediate onset of action and they rapidly 
reduce sex hormone levels without the initial estrogen surge (18), not causing flare-up effect. 
Currently, GnRH-ant are available as injectable formulation and increasingly as oral nonpeptide 
forms (9, 18). 
Cetrorelix (CET) is a basic peptide GnRH-ant administered via subcutaneous injections. Taniguchi 
et al. compared the efficacy of CET and buserelin acetate, a GnRH-a, in reducing the proliferation 
of endometriotic and endometrial stromal cells obtained from OEs. Both treatments decreased cell 
proliferation by reducing the levels of tumor necrosis factor-α (TNF-α) in endometrial stromal cells, 
whereas ectopic endometriotic stromal cells did not respond. Moreover, both treatments did not 
inhibit TNF-α–induced interleukin (IL)-8 production in endometriotic implants (19). Differently, in 
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another pre-clinical study on rats with peritoneal implants, the administration of CET or leuprolide 
for 8 weeks showed similar efficacy in causing the regression of implants size of experimental 
endometriotic lesions, and in reducing their amount of stromal tissue and glandular tissue (20). 
Kϋpker et al. evaluated CET (3 mg, subcutaneous weekly for 8 weeks) in a clinical trial including 
15 patients with symptomatic endometriosis. Among them, 10 women (67%) have endometriosis at 
rAFS stages III (n=4) and IV (n=6). All the women had a complete improvement of pain during 
treatment. Although they did not experienced AEs related to hypoestrogenism, 3 women (20%) 
suffered headache only immediately after initial treatment, and 3 women (20%) experienced uterine 
bleeding. At a second-look laparoscopy, lesions regression was observed in 60% of patients (9/15) 
and all the endometrial biopsies performed after the end of treatment showed glandular and stromal 
atrophy. Only 6 patients (40%) still have rAFS stages III (n=1) and IV (n=5)(21).  
Elagolix is an oral short-acting nonpeptidic GnRH-ant. It is the most investigated GnRH-ant in 
women with endometriosis. A controlled, single- and multiple-dose study with sequential dose 
escalation including 55 healthy premenopausal women was assessed the safety and 
pharmacokinetics of elagolix. Elagolix was well tolerated and rapidly bioavailable after oral 
administration; it caused a rapid decline in serum gonadotropins and E2 concentrations. Daily (50-
200 mg) or twice-daily (100 mg) administration for 7 days maintained low E2 levels (17 ± 3 to 68 ± 
46 pg/ml) in most subjects during late follicular phase, which were rapidly reversed after 
discontinuation (22). Subsequently, a phase II trial by Diamond et al. evaluated elagolix (150 or 
250 mg once daily for 12 weeks) in comparison to placebo in 155 patients with surgically 
confirmed endometriosis. Elagolix caused a reduced level of dysmenorrhea and dyspareunia at 
weeks 8 and 12 compared to placebo, but no significant difference was observed for chronic pelvic 
pain. Moreover, BMD was minimally but significantly reduced after the hormonal therapy (23). In a 
randomized double-blind study, with 24-week treatment and 24-week posttreatment period, Carr et 
al. compared the efficacy of elagolix and depot medroxyprogesterone acetate-subcutaneous 
(DMPA-SC) in 252 women with endometriosis-related pain. Elagolix was found to have minimal 
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impact on BMD over a 24-week period and showed similar efficacy on pain compared to DMPA-
SC (24).  
In a recent publication, Taylor et al. reported the results of two multicenter double-blind, 
randomized, placebo-controlled phase 3 trials (Elaris Endometriosis I and II) (25). In both, elagolix 
(150 mg once daily or 200 mg twice daily) was compared with placebo in 1285 women with 
surgically diagnosed endometriosis and moderate or severe endometriosis-associated pain. In the 
first study, the percentage of women who had a clinical response with respect to dysmenorrhea and 
chronic pelvic pain were 46.4% and 50.4% in the lower-dose elagolix group, 75.8% and 54.5% in 
the higher-dose elagolix group, 19.6% and 36.5% in the placebo group (P<0.001 for all 
comparisons). In the second study, the percentage of women who responded to dysmenorrhea and 
chronic pelvic pain were 43.4% and 49.8% in the lower-dose elagolix group, 72.4% and 57.8% in 
the higher-dose elagolix group, 22.7% and 36.5% in the placebo group (P<0.001 for all 
comparisons). Moreover, women receiving elagolix had higher rates of hot flushes (mostly mild or 
moderate), higher levels of serum lipids, and greater decreases from baseline in BMD than did those 
receiving placebo.  
Currently, two ongoing phase III trials, are evaluating the safety and efficacy of both elagolix alone 
and elagolix plus E2 and NETA over 24 months of treatment for the management of moderate to 
severe pain in premenopausal women with endometriosis (NCT03343067 and NCT03213457). 
Other GnRH-ants are currently under investigation. Relugolix (TAK-385) is a new non-peptide, 
orally selective GnRH-a. After having demonstrated the continuously and reversibly suppression of 
the hypothalamic-pituitary-gonadal axis (26), it is being tested in clinical trials. A randomized, 
double-blind, placebo-controlled phase trial III is testing the efficacy and safety of relugolix (40 
mg, once-daily) co-administered with either 12 or 24 weeks of low-dose E2 (1.0 mg) and NETA 
(0.5 mg), compared with placebo in women with endometriosis associated pain (NCT03204318).  
Among other novel drugs, a prospective, dose-finding, randomized, parallel group, double-blind, 
placebo-controlled phase IIb study is testing the efficacy and safety of OBE2109, another GnRH-
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ant, for the treatment of 330 women with moderate-to-severe endometriosis associated pain 
(NCT02778399); the results are awaited. 
 
4.2 Aromatase inhibitors 
The endometriotic tissue expresses all the genes needed to produce estrogens, differently from 
eutopic endometrium. Aromatase P450 is a critical enzyme responsible of the conversion of 
androstenendione and testosterone to estrone and E2 (27). Elevate levels of aromatase mRNA have 
been demonstrated in ectopic endometriotic implants (28). Based on this background, aromatase 
inhibitors (AIs) have been investigated for the treatment of women with endometriosis, showing to 
decreases E2 level and to reduce endometriotic implants growth and invasion (29).  
In a systematic review, Ferrero et al. identified ten clinical trials investigating the use of AIs for the 
treatment of endometriosis (183 women). This review demonstrated that the continuous 
administration of two AIs, anastrozole and letrozole, was effective in reducing the severity of 
endometriosis-related pain symptoms and ameliorated women’ quality of life (30). However, the 
use of AIs was limited by the high incidence of AEs. The ESHRE guidelines suggest the therapy 
with AIs in combination with COCs, progestins or GnRH-as in women with rectovaginal 
endometriosis, refractory to other medical or surgical treatment (31).  
Hefler et al. evaluated the administration of anastrozole in a vaginal suppository for the treatment of 
10 patients with histologically confirmed rectovaginal endometriosis. After 6 months of treatment, 
the patients had a significant improvement in dysmenorrhea and quality of life. The volume of the 
rectovaginal nodules decreased in three patients, remained stable in three and increased in three 
(32). Currently, a randomized, double-blind, parallel- group, multicenter phase IIb study is 
assessing the efficacy and safety of BAY98-7196, an intravaginal ring with different dose 
combinations of anastrozole (300-600-1050 µg/d) and levonorgestrel versus placebo and leuprolide 
acetate in women with symptomatic endometriosis over a 12-week treatment (NCT02203331). The 
administration of these hormonal combination by vaginal route may be particularly effective in 
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women with rectovaginal endometriosis. In fact, a local administration in close proximity to the 
endometriotic nodules could result in higher concentration of the drug in this localization (33). 
Another ongoing randomized parallel phase IV trial is evaluating the combination of anastrazole 
plus leuprolide acetate for the prevention of endometriosis recurrence compared with leuprolide 
acetate as monotherapy (NCT01769781). 
Letrozole is AI most frequently investigated for the treatment of endometriosis. A randomized 
prospective open-label study including 35 women with rectovaginal endometriosis demonstrated 
that the intensity of both chronic pelvic pain and deep dyspareunia were significantly lower after 3 
and 6 months of therapy when compared with baseline values in patients receiving letrozole in 
combination with NETA or triptorelin. In addition, more patients treated this double regimen rated 
their treatment as satisfactory or very satisfactory (64.7%) as compared with patients receiving 
letrozole and triptorelin (22.2%; p = 0.028). Moreover, there was a greater reduction in the volume 
of endometriotic implants in patients receiving both letrozole and triptorelin than in those receiving 
letrozole and NETA (34). A prospective, non-randomized clinical trial including eight patients who 
received a 12-month treatment with letrozole and NETA demonstrated similar results for the 
reduction of the volume of the rectovaginal nodules infiltrating the rectum. Moreover in this study, 
there was no increase of more than 5% in the volume of the nodules (35).  
The combination of letrozole and NETA has also been tested for the treatment of OEs. In a 
prospective patient-preference study, the mean percentage reduction in OEs volume was greater in 
patients receiving the double regimen (- 74.4 ± 4.2% and - 46.8 ± 3.8%, respectively, p < 0.001) 
than in those receiving only the progestin. However, in both groups, there was not a complete 
regression of OEs (36). In another small study, five reproductive-age women with recurrent OEs 
and chronic pelvic pain received a 6-month treatment with letrozole, DSG and EE after a previous 
failure of surgery and hormonal approaches. During this study, two patients had complete 
regression of OEs after 3 and 6 months, respectively. Moreover, no recurrences were reported 
during the follow-up of 2 years (37). 
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AIs have also been used for preventing the recurrence of endometriosis after surgical treatment, but 
the results are controversial. Two randomized controlled trials demonstrated that the post-surgical 
administration of AIs as monotherapy or in combination with GnRH-as decreased more the risk of 
recurrence of endometriosis when compared with single GnRH-as or danazol (38, 39). However, in 
another randomized controlled trial, the use of AIs for 2 months after surgery did not succeed in 
decreasing the risk of disease recurrence in comparison with GnRH-as or placebo (40).  
 
4.3 Selective estrogen receptor modulators  
Selective estrogen receptor modulators (SERMs) directly bind to estrogen receptor (ER)-α and/or 
ER-β in target cells, exerting estrogen- or anti-estrogen-like actions.  
Bazedoxifene is a third-generation SERM that is effective in preventing BMD loss and osteoporotic 
fractures in postmenopausal women, and it does not cause negative effects on breast or 
endometrium (41). Its activity of antagonizing estrogen stimulation on endometrial cells has led this 
drug to be investigated for the treatment of endometriosis. In a pre-clinical study on mice, the 
treatment with bazedoxifene for 8 weeks cause a significant reduction in the size of endometriotic 
lesions. Moreover, proliferating cell nuclear antigen mRNA and estrogen receptor mRNA 
expressions were decreased, demonstrating an high inhibition of estrogen-mediated cell 
proliferation (42). In another pre-clinical study, bazedoxifene in association with conjugated 
estrogens succeeded in causing regression of endometriotic implants. The authors showed also a 
reduction in stem cell recruitment to the endometriotic lesions (43). Another group investigated the 
efficacy of bazedoxifene as monotherapy in comparison with conjugated estrogens on ectopic 
endometrial implants of mice affected by experimental endometriosis, not founding significant 
difference in size of lesions between the two groups after the end of the therapy (44).  
In a pre-clinical study, the use of raloxifene (10.0 mg/kg), another SERM, in mice with induced-
endometriosis, obtaining a significant implant regression (45). Moreover, another randomized, 
placebo-controlled, single blind trial evaluated its efficacy in comparison with anastrozole, 
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concluding that both hormonal therapies obtained a similar lesions decrease (46). These promising 
results led to the investigation of raloxifene in 93 women with endometriosis. A randomized 
controlled trial, including patients with histologically confirmed endometriosis (ASRM stage I-IV) 
and chronic pelvic pain, evaluated a 6-month therapy with raloxifene (180 mg, daily) or placebo. 
This study was interrupted prematurely because patients belonging to the raloxifene group 
experienced worsening of pain. Moreover, women receiving raloxifene underwent second surgery 
for endometriosis significantly sooner than those in the placebo group. It has been assumed that   
raloxifene in human, differently from rodents that have an estrous cycle, may not prevent ovulation. 
Thus, subsequent ovarian estrogen production may continue and, in some cases, increase in 
response to the action on receptors of this drug, worsening patients’ symptoms (47).  
 
4.4 Selective progesterone receptor modulators 
 
Selective progesterone receptor modulators (SPRMs) bind to the progesterone receptor to block or 
modify downstream its effects inducing amenorrhea through selective block of endometrial 
proliferation without the systemic effects of estrogen suppression (48). It is known that SPRMs may 
induce endometrial changes known as progesterone modulator-associated endometrial changes 
(PAECs). From available data, these induced endometrial alterations do not seem to be precursors 
of precancerous lesions, reverting back to normal within 6 months after ending the treatment (49). 
Mifepristone and other SPRMs antagonize estrogen activities in the endometrium of primates (50-
53), induce endometrial atrophy and amenorrhea in ovariectomized, estrogen-substituted monkeys 
(50, 53-61) and reduce the size of endometriotic implants in primate model (53). 
A prospective open-label trial assessed the endocrine and clinical responses to the administration of 
mifepristone for 3 months for the treatment of 16 women with endometriosis. It caused an 
improvement of pelvic pain in all patients without significant changes in the extent of implants, 
assessed by laparoscopy after the end of the treatment (56). Subsequent studies confirmed these 
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findings demonstrating not only an improvement in endometriosis-related pain symptoms, but also 
a regression of the lesions (55, 57).  
Asoprisnil, another SPRM with a partial agonist/antagonist progestin activity, is under investigation 
for the treatment of endometriosis. It is known from studies on primates that this drug causes the 
suppression of endometrial proliferation and promotes amenorrhea by targeting the endometrium 
(58). In an in vivo rat model, asoprisnil did not succeed in reducing of the volume of OEs (60). In a 
randomized placebo-controlled trial this drug (5, 10, and 25 mg) demonstrated a higher decrease of 
dysmenorrhea-related to endometriosis in comparison with placebo (61). Anyway, the trials on this 
drug were stopped for the presence of some cases of endometrial hyperplasia (62). Thus, at the 
moment very limited evidence is available on the use of asoprisnil for treating endometriosis and 
better-designed studies are mandatory to investigate its safety and efficacy.  
Among the other SPRMs, ulipristal acetate (UPA) has been investigated in this setting, 
demonstrating to be able to cause the regression and atrophy of endometriotic lesions in rodents 
(63). Although it is known from clinical trials for treating uterine fibroids that UPA may be 
responsible of mild to moderate AEs (headache, breast tenderness and hot flushes) (64), recently 
four cases of serious liver injury (three of which ended in liver transplantation) have been reported. 
Therefore, in December 2017, the Pharmacovigilance Risk Assessment Committee of the European 
Medicines Agency (EMA) has started to evaluate whether this drug could be the cause of liver 
injury. Currently, no clinical data on UPA for the treatment of endometriosis are available. 
Tanaproget, another SPRM, succeeded in causing the reduction of endometriotic implants in 
rodents, but no clinical trials have been never organized in human (65). 
 
 
 
5.0 Anti-angiogenetic drugs 
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Angiogenesis is a fundamental mechanism involved in the development and growth of 
endometriotic implants. Thus, there is a solid rational to study drugs targeting the angiogenetic 
pathway for the treatment of endometriosis (66).  
Vascular endothelial growth factor (VEGF) is the most important molecule involved in 
angiogenesis (67, 68). Bevacizumab is a recombinant humanized monoclonal antibody that blocks 
angiogenesis by inhibiting serum VEGF (69). In the murine model, it inhibits the development of 
endometriotic lesion, decreasing cell proliferation and increasing apoptosis, and reduces vascular 
density and VEGF levels in peritoneal fluid (70). Another recent pre-clinical study demonstrated 
that bevacizumab is as effective as GnRH-as in inducting apoptosis of ectopic endometrial cells, 
and, thus, the regression of lesions (38, 71). It was recently shown that the administration of oral 
rosuvastatin and intraperitoneal bevacizumab in rats causes an higher regression of implants than 
oral progesterone compounds (72).  
Tyrosine kinase inhibitors (TKIs) inhibit the catalytic activity of tyrosine kinases receptor, such as 
VEGFRs, platelet-derived growth factor receptors (PDGFRs), and stem cell factor receptor (c-KIT), 
which are all deeply involved in angiogenesis (73). In a pre-clinical study, sorafenib succeeded in 
reverting proliferation, migration and neoangiogenesis of ectopic mesenchymal stem cells obtained 
from ectopic and eutopic endometrial tissue (74). Moreover, it was effective without affecting 
ovarian reserve in mice with endometriosis (75). A comparative study in the rat model investigated 
the effects of other TKIs on endometriotic tissue morphology and histological characteristics as 
well as on ovarian reserve. At the end of the treatment, the endometriosis score was significantly 
decreased in rat treated with pazopanib versus other investigated drugs and by sunitinib versus 
sorafenib and normal saline but not by sorafenib. A similar reduction of the VEGF score was 
achieved using pazopanib, sunitinib, and sorafenib compared to normal saline. Moreover, ovarian 
follicle number was not significantly affected by any drug evaluated in the study (76). The efficacy 
of sunitinib on endometriotic lesions compared with no medication or danazol was tested in another 
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pre-clinical study. Both sunitinib and danazol decreased the volume and the extent of rats’ implants, 
the severity and total score of adhesions due to the disease (77).  
Mammalian target of rapamycin (mTOR) is a protein kinase that critically controls cellular growth, 
proliferation, and survival. Rapamycin, a bacterial macrolide, inhibits this pathway, excreting also 
anti-angiogenic activity (78). In the animal model, rapamycin decreased the size of the 
endometriotic implants. Moreover, it inhibited VEGF-induced angiogenesis, as indicated by the 
suppression of endothelial cell sprouting in vitro and the reduction of microvessel density in 
implants (79). Temsirolimus and everolimus, two inhibitors of mTOR/AKT pathway, showed to 
decrease endometriotic cell proliferation both in vitro and in a mouse model (80, 81). 
Among other anti-angiogenic compounds, TNP-470, a synthetic analogue of the antibiotic 
fumagillin, significantly decreased the microvessel density and the number of endometriotic lesions 
in the chicken chorioallantoic membrane (73). ICON is an immunoconjugate molecule which 
selectively binds tissue factor, an important modulator of angiogenesis in endometriosis (82). ICON 
decreased the size of endometriotic implants by exerting vascular disruption without causing 
apparent toxicity, reducing fertility, or exerting teratogenicity (83). 
It has been demonstrated that the important role of dopamine (D) and its receptor 2 in the 
modulation VEGF-mediated angiogenesis in endometriosis (84-86). For this reason, the 
administration of D-receptor 2 agonist has been proposed in animal models and women (87-89). 
Cabergoline and quinagolide, nonergot-derived dopamine agonists, succeeded in decreasing the size 
of endometriotic lesion of mice, inhibiting angiogenesis (87). Moreover, an experimental study 
conducted in female nude mice demonstrated that the treatment with cabergoline reduced active 
endometriotic lesions and cellular proliferation index, decreasing neoangiogenesis. At 
morphological level, significant changes in gene expression and a lower degree of VEGFR-2 
phosphorylation than in controls were demonstrated (88). Currently, an ongoing pilot phase II study 
is evaluating the efficacy and safety of cabergoline in association with NETA for the treatment of 
endometriosis-associated pain in women with endometriosis (NCT02542410). 
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A proof-of-concept study tested the efficacy of quinagolide, administered in a titrated manner (25-
75 μg/d) for 18-20 weeks, for decreasing the size of peritoneal lesions in women with 
endometriosis. This drug induced a decrease of 69.5% in the lesions size. At second-look 
laparoscopy, the histologic study demonstrated tissue degeneration, with a down-regulation of 
VEGF/VEGFR2, three proangiogenic cytokines (CCL2, RUNX1, and AGGF1) and plasminogen 
activator inhibitor-1, a potent inhibitor of fibrinolysis (89). 
 
6.0 Inhibition of inflammation 
Cyclooxygenase (COX) is the enzyme responsible of the metabolic conversion of arachidonic acid 
to PGs. PG-E2 is a major mediator of inflammation and angiogenesis. The ectopic endometrial 
tissue is characterized by overproduction of prostaglandins, cytokines and chemokines (2). Non-
selective NSAIDs have been largely studied for the treatment of endometriosis-associated pain and 
their mechanism of action consists in inhibiting the synthesis of prostaglandins at both the COX-1 
and COX-2 sites (90). 
Parecoxib, a selective COX-2 inhibitor, has been investigated for treating endometriosis in a rat 
model, showing to reduce size and microvessel density of implants, and also the expression of 
VEGF, Flk-1 and PG-E2 (91). Promising findings were also observed with celecoxib that was able 
to induce apoptosis in cultures of endometrial epithelial and stromal cells (92, 93) and to decrease 
number and size of peritoneal implants in mouse model (94-96).  
TNF-α is an inflammatory cytokine responsible for the activation of transcription factors involved 
in inflammation. It has also an important role in the proliferation ectopic and eutopic endometrial 
cells, and in facilitating cell adherence in implants (97, 98). Two human recombinant TNF-α 
antagonists, TNFRSF1A and c5N, showed to exert inhibitory effect on endometriotic lesions 
without affecting the menstrual cycle in baboons (99, 100). Moreover, etanercept, a fusion protein 
consisting of human recombinant soluble TNF receptor 2 conjugated to a human Fc antibody 
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subunit, was efficacious in reducing the volume and histopathologic scores of rat’s implants, 
decreasing also serum levels of VEGF, IL-6, and TNF-α (101-103).  
Furthermore, infliximab, a monoclonal antibody directed against TNF-α was efficacious in 
decreasing the size of endometriotic lesions and the plasma levels of nitric oxide (NO) and in 
increasing the plasma levels of asymmetric dimethylarginine (ADMA) in the rats with 
endometriosis (104). These observations paved the way to a randomized placebo-controlled trial 
including 21 women with severe pain due to rectovaginal endometriosis of at least 1 cm in 
diameter. Differently from previous studies, infliximab did not modify size or number of 
endometriotic implants and did not improved pain associated to DIE (105).  
p38 mitogen-activated protein kinase (p38 MAPK) is an intracellular signal-transducing molecule 
that causes pro-inflammatory cytokines expression, leukocyte adhesion and chemotaxis of 
inflammatory cells (106, 107). Several studies suggest its contribute in the pathogenesis of 
endometriosis (108-110). In mice, FR 167653 and SB203580, two p38 MAPK inhibitors, succeeded 
in suppressing peritoneal inflammation, and in decreasing the weight and size of the endometriotic 
implants. Moreover, these drugs significantly reduced the levels of IL-1β, TNF-α, MMP-2 and 
MMP-9 in peritoneal fluid and cells (111, 112). 
AKR1C3 is a gene that encodes a member of the aldo/keto reductase superfamily. This enzyme 
catalyzes the reduction of several PGs, such as PG-D2, PG-H2 and the oxidation of 9-α,11-β-PG-
F2 (113). An ongoing randomized, placebo-controlled, double-blind, dose-response study is 
assessing the efficacy and safety of different oral doses of BAY1128688 in women with 
symptomatic endometriosis over a 12-week treatment period (NCT03373422). 
 
7.0 Immunomodulation 
Nuclear factor (NF)-kB family includes a group of transcription factors significantly involved in the 
inflammatory and immune processes. It has a fundamental role in development and establishment 
of endometriotic implants (114). Several inhibitors of NF-kB, such as IkB protease inhibitor 
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(TPCK), thalidomide, BAY 11-7085, the urinary preparation human chorionic gonadotropin A 
(hCG-A), pyrrolidinedithiocarbamate (PDTC), and costunolide, have been tested in vitro and on 
animals for the treatment of endometriosis. All these studies showed a reduction of the expression 
of genes that regulate the production of inflammatory cytokines, extracellular matrix 
metalloproteinases (MMPs), apoptosis inhibitors, and VEGF (115-121). 
Among natural immunomodulators, curcumin is a polyphenolic molecule derived from Curcuma 
longa that it is able to inhibit NF-kB and induce a p53-mediated apoptosis (122). This drug modules 
also VEGF and MMP-3 expression and decreases the production of inflammatory molecules, such 
as IL-6, IL-8, MIF, MCP-1, ICAM-1, and VCAM-1 in cultures of human ectopic endometriotic 
stromal cells (123-125). In vivo curcumin demonstrated to decrease the size of endometriosis 
implants (126). Specifically, the effect on the apoptotic pathway of curcumin was studied in mice in 
comparison with colecoxib. Curcumin increased the Bax/Bcl-2 ratio, the expression of p53, and the 
apoptotic index of stromal and epithelial endometriotic cells significantly more than the COX-2 
inhibitor (125). Recently, it was shown that the combination of curcumin and deferoxamine, an 
iron-chelating agent, reduces implant size and cell proliferation in rats with endometriosis (127).  
DLBS1442 is a bioactive fraction extracted from the fruit of the native Indonesian plant, which has 
immunomodulatory and anti-inflammatory activities as well as antiangiogenic and apoptosis-
inducing effects. In mice model, DLBS1442 showed to inhibit angiogenesis and cell migration in a 
dose-dependent manner. Regarding its mechanism of action, it targeted the eicosanoid signaling 
pathway by reducing the NFκB transcription level and inducible nitric oxide synthase (128). After 
being investigated in a clinical trial to treat dysmenorrhea (129), an ongoing prospective, 
randomized, double-blind controlled study is testing its efficacy for the treatment of pain in patients 
with suspected endometriosis (NCT01942122).  
A randomized, placebo-controlled, single blind, experimental study assessed the efficacy of 
imiquimod, an imidazoquinoline which induces monocytes, macrophages, and dendritic cells to 
produce cytokines, in experimental endometriosis on rats. The intraperitoneal administration of 
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imiquimod significantly reduced the volume of endometriotic lesions compared to controls (130). A 
recent study evaluated an inhibitor of c-Jun N-terminal kinase, bentamapimod (AS602801), which 
acts on multiple immune pathways, in animal endometriosis model. AS602801 caused regression of 
48% of lesions, causing a decrease of inflammatory cytokines. In addition, it enhanced natural killer 
cell activity, without exerting apparent negative effects on uterus (131). 
Recently, V-Endo, a tableted preparation derived from hydrolyzed, heat-inactivated, pooled blood 
of women with endometriosis has been introduced. When taken orally it is postulated to cause the 
immune tolerance and anti-inflammatory effect as a result. An ongoing single-arm I-II trial in 
recruiting patients for testing it. The primary outcome is its efficacy in treating pelvic pain 
(NCT03340324). 
 
7.0 Antioxidants agents 
Oxidative stress has been demonstrated to contribute in the development and progression of 
endometriosis. In fact, the increased production of inflammatory mediators such as cytokines, 
reactive oxygen species and prostaglandins (PGs) characterizes endometriotic implants (132). Thus, 
a large variety of antioxidants have been tested in vitro (133).  
Statins, competitive inhibitors of the 3-hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, 
exert intrinsic antioxidant activity and exhibit anti-proliferative and anti-angiogenic activity at high 
doses (134). In a pre-clinical study conducted on mice, endostatin, a proteolytic fragment of 
collagen XVIII, suppressed the growth of endometriotic implants by 47% compared with controls 
(135). Simvastatin, another largely used statin, significantly inhibited the proliferation of 
endometriotic stromal cells, reducing their adhesion to collagen fibers (136). In nude mice, the 
administration of simvastatin (5 or 25 mg/kg/day) for 10 days caused a dose-dependent reduction of 
the number and size of endometrial implants by decreasing MMP-3 expression. At the highest dose, 
the number and the volume of endometrial implants was decreased by 87% and by 98%, 
respectively (137).  
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In two preclinical studies on rats, atorvastatin was effective in inducing regression of endometriotic 
implants. In a prospective randomized-controlled study, animals receiving atorvastatin at high-dose 
(2.5 mg/kg) had a significant decrease of implants areas and of VEGF levels of peritoneal fluid 
(138). In the other study, its administration caused a decrease of VEGF and MMP-9 expressions 
and an increase of MMP-2 tissue inhibitor expression (139). 
Metformin has anti-inflammatory activity and is able to modulate the ovarian steroid production. In 
a pre-clinical study on animal, Yilmaz et al. showed that metformin decreases the size and the 
number of endometriotic lesions by enhancing the levels of superoxide dismutase, and MMP-2 
tissue inhibitor, and by reducing levels of VEGF and MMP-9 (140).  
Thiazolidinediones target with a high affinity peroxisome proliferator-activated-γ (PPAR-γ) 
receptors which are involved in cell growth, angiogenesis and has anti-inflammatory activity (141). 
In the animal model, the treatment with tosiglitazone, ciglitazone or pioglitazone succeeded in 
inhibiting proliferation and in augmenting apoptosis of endometriotic cells. Moreover, these drugs 
reduced growth and caused regression of established implants when compared with controls (96, 
141-143). 
Among vitamins, elocalcitol (in miglyol orally, once a day, 5 days a week), a vitamin D receptor 
agonist with low calcemic liability, was able to decrease total lesion weight up to 70% after two 
weeks of treatment in mice with experimental endometriosis. Exploring its mechanism of action, it 
was demonstrated that elocalcitol reduced cell adherence to collagen, the recruitment of 
macrophage and the secretion of inflammatory cytokines in the peritoneum of the treated animals 
(144). 
A peculiar gene expression pattern has demonstrated a decrease in uptake and metabolism of 
vitamin A, a molecule with immune-modulatory and anti-inflammatory proprieties, in women with 
endometriosis. More, its alteration may provide a partial explanation to the resistance to apoptosis 
of endometriotic cells (145, 146). In mice with induce endometriosis, the 17-day administration of 
retinoic acid decreased the number of endometriotic lesions in comparison to a control group. 
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Moreover, mice receiving the vitamin A had a lower peritoneal IL-6 and MCP-1 concentrations, 
and a higher expression of CD38, CD11b, and F4/80 on macrophages (147). In another pre-clinical 
study, this drug confirmed to reduce the volume of established endometriotic implants (75).  
In vitro, omega-3 fatty acids inhibit the release of inflammatory mediators in endometrial stromal 
cells (148). A prospective, randomized experimental study evaluated the anti-inflammatory effect of 
n-3 eicosapentaenoic acid in comparison with n-6 linoleic acid in the experimental rat model of 
endometriosis. The mRNA of MMPs, IL-1β, IL-1 receptor, prostaglandin E synthase and NF-kB 
expressions were decreased more in the group receiving the omega-3 fatty acids (149). Another 
study demonstrated that both endogenous and exogenous eicosapentaenoic acid-derived 
polyunsaturated fats protect against the development of implants through their anti-inflammatory 
effects. In particular, the 12/15-12/15-lipoxygenase-pathway metabolites of eicosapentaenoic acid 
seem to be important mediators to suppress the progression of implants (150). A further study in rat 
showed that omega-3 polyunsaturated fatty acids induced lesions regression more than 1,25-
dihydroxyvitamin-D3 (151). A cohort of women with endometriosis was treated for three months 
with a combination of antioxidants, including omega -3 and- 6 fatty acids. The authors showed a 
significant reduction of the symptoms as well as in PGE2 and CA-125 serum levels of patients 
treated with the dietary composition than controls (152). 
N-acetylcysteine is an antioxidant that downregulates inflammatory protein production and gene 
expression (148). In an observational cohort study, women with endometriosis received N-
acetylcysteine (600 mg three times a day, 3 consecutive days a week) for 3 months. After 3 months, 
the administration of N-acetylcysteine showed that OEs diameter were slightly reduced (-1.5 mm) 
in comparison with a significant increase (+6.6 mm) in the untreated patients (153). 
The antioxidant and anti-inflammatory effects of α-lipoic acid was studies in a controlled 
experimental endometriosis-induced rat model by evaluating biochemical and histopathologic 
parameters. The serum total oxidant status and oxidant stress index levels, the endometrial implant 
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volumes, the serum and peritoneal TNF-α concentrations, and the histopathologic scores were 
significantly lower in the experimental group (154).  
Resveratrol is a phytoalexin derived from grapes with potential antioxidant activity. Its anti-
inflammatory effect of resveratrol is mediated by several mechanisms including the inhibition of 
(NF)-kB activation. In animal models of endometriosis, the supplementation of resveratrol 
displayed to decrease the number and volume of endometrial implants, suppressing inflammation 
and decreasing cell proliferation and survival of ectopic endometriotic cells (155). In a small open-
label clinical trial, 12 women with endometriosis who failed to obtain pain relief during COC use 
(drosperinone 3 mg and EE 30 μg) received the addition of resveratrol (30 mg/day). The patients 
had a significant reduction in pain scores, with 82% of them reporting complete resolution of 
dysmenorrhea and pelvic pain after 2 months of therapy (156). Recently, these results have not been 
confirmed by another study in which resveratrol (40 mg/day, 22 patients) was evaluate in 
comparison with monophasic COC (levonorgestrel 0.15 mg/EE 0.03 mg, 22 patients, showing no in 
the two groups regarding pain scores at VAS (157). 
 
8.0 Epigenetic inhibitors  
Epigenetic inhibitors are an early investigated target in endometriosis (158). They target histone 
deacetylases, a family of enzymes that control the acetylation status of histones, modulating cell 
survival and proliferation (159). It was also demonstrated that histone deacetylases are involved in 
controlling the expression of steroid hormone-related genes (160), justifying their investigation in 
endometriosis. In a pre-clinical study, trichostatin A exerted antiproliferative activity against 
endometrial stromal cells with more potent and longer lasting effect than other drugs, such as 
SPRMs and N-acetylcysteine. In particular, it induced cell cycle arrest by blocking COX-2 (161, 
162). In another pre-clinical study, Lu et al. observed that its use significantly decreased the size of 
implants, as well as improved the response to noxious thermal stimulus (163). Moreover, valproic 
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acid, another potent histone deacetylase inhibitor, was effective in decreasing the size of 
endometriotic implants and was well tolerated in rats treated (164).  
 
9. Conclusion  
Almost all currently available treatments of endometriosis are suppressive and not curative. For this 
reason, research is focalized on finding new therapeutic options. Several investigational drugs 
targeting specific pathophysiological mechanisms involved in endometriosis development, such as 
inflammation, neoangiogenesis, or apoptosis, are being investigated in early and late clinical trials 
for the treatment of endometriosis. However, most of them have been tested just in vitro or in 
animals and their clinical use in women is far to be applicable.  
 
10. Expert opinion  
The development, maintenance and progression of endometriosis is due to a variety of altered 
mechanisms including cell proliferation, immune function, apoptosis, invasion capacity and 
angiogenesis. The growing knowledge of different molecular pathways involved in endometriosis 
development paved the way for the investigation of new drugs. 
Patients with endometriosis require a chronic therapy and, therefore, when choosing the best 
treatment efficacy in improving pain should be balanced with cost and a good safety-profile (9). If 
COCs have been used for decades as the first-line treatment for symptomatic endometriosis, 
progestins are increasingly and successfully employed as monotherapy. Currently, it controversial 
whether COCs should be preferred or not to progestins as monotherapy (165, 166). In fact, it has 
been supposed that COCs, causing a supraphysiological levels of estrogen, may be theoretically 
responsible of an estrogen dominance in presence of progesterone resistance, leading to an eventual 
progression of endometriosis under therapy (165). Anyway, more studies are needed to draw 
conclusion on this topic. 
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Anyway, almost all currently available treatments of endometriosis are suppressive and not 
curative. In fact, they are associated with the temporary relief of symptoms during treatment, but at 
its discontinuation, the recurrence of symptoms is common. Moreover, current treatment options for 
endometriosis-associated pain, excepting NSAIDs, are contraceptive. Thus, these therapies are not 
suitable for patients wishing to become pregnant.  
Overall, medical therapy with progestins enables satisfactory long-term pain control in around two-
thirds of symptomatic women. For patients refractories to traditional first-line therapies the 
administration of GnRH-as is suitable, but is associated to a less favorable profile of tolerability.  
Thus, new alternative treatment options are demanding. 
Over the last 20 years research has focused on developing drugs targeting pecific critical pathways 
of endometriosis (167). Theoretically, these compounds should act on the hormonal and 
immunological environment of endometriotic implants, downregulating cell proliferation and 
enhancing apoptosis, re-normalizing their invasive mechanisms and upregulated adhesion or 
inhibiting angiogenesis. 
The most investigated agents are GnRH-ant and AIs. After promising findings from phase II 
studies, Elaris Endometriosis I-II trials (25) showed that both higher and lower doses of elagolix 
were effective in improving dysmenorrhea and chronic pelvic pain during a 6-month period in 
women with endometriosis-associated pain. However, the treatment with two doses of elagolix 
were associated with higher hypoestrogenic AEs. Currently, ongoing phase III trials have to 
confirm its efficacy (NCT03343067 and NCT03213457). Anyway, the data available suggest that 
elagolix at 150 mg once daily may have the potential for longer-term use for the management of 
endometriosis-associated pain, without the need for add-back therapy. Currently, no randomized 
controlled trials exist yet to compare GnRH-ant with COCs or progestins. Thus, no inferiority 
studies to compare them with other treatment options are required in the near future. 
AIs has shown promising results in terms of endometriosis-related pain improvement, but, their 
clinical use is strongly limited by the high AE rate. However, the research of alternative delivery 
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formulation is attractive. Currently, a combination of anastrozole and levonorgestrel in a vaginal 
ring is under evaluation (NCT02203331) and may represent an intriguing future option.  
The use of SERMs and SPRMs to treat endometriosis is unlikely to become a first-line strategy due 
to the unsatisfying results observe in laboratory/animal studies (48) (103, 168). Furthermore, these 
compounds share the same receptors and therapeutic mechanisms with the existing agents, 
including the potential contraceptive effect. 
Several antiangiogenic agents have been tested in animal models, showing efficacy in reducing the 
establishment and maintenance of endometriotic implants. However, the role of inhibiting 
angiogenesis in humans with endometriotic lesions present for years at the time of diagnosis 
remains unclear. Furthermore, owing to their severe AEs related to interference with physiologic 
angiogenesis, their translation into human research has been limited (169-171). A small proof-of- 
concept study demonstrated promising findings in terms of efficacy and safety with the use of 
quinagolide, a dopamine agonist, to treat patients with peritoneal endometriosis (89); however, 
these preliminary results have to be confirmed in larger, well-designed trials.  
Among anti-inflammatory drugs, TNF-α blockers have shown good efficacy in animal studies. In 
particular, etanercept is currently administered with a good safety profile in the treatment of chronic 
inflammatory diseases in humans, but no trials in women with endometriosis has been performed. 
On the other hand, the promising results of infliximab in pre-clinical study have not been confirmed 
in a small clinical trial on women (168).  
Oxidative stress may participate to the development and progression of endometriosis, and, thus, it 
may a suitable target for the treatment of endometriosis (132). The efficacy of several antioxidants 
to relieve endometriosis-associated pain and to reduce endometriotic lesions has been assessed, but 
only poor evidence exists to support their clinical application. In particular, it appears rational the 
investigation of statins, metformin and tiazolinediones, because they exert antioxidant and anti-
angiogenic activities, they are not expensive and are largely available. After having been tested 
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successfully in animal with endometriosis, large further studies in vivo are needed to draw 
conclusion on their efficacy in women with endometriosis. 
In addition, as aberrant methylation of the progesterone receptor gene seems to take part in the 
process of specific gene silencing in endometriosis (158), demethylation agents and histone 
deacetylase inhibitors have been proposed as alternative possible options. It seems be promising the 
use of valproic acid in animals because of its efficacy and its safety-profile. Although the 
interesting results from a cases series of women with adenomyosis treated with valproic acid (172), 
no trials on its use for endometriosis exist, thus, any beneficial effect of this drug has to be 
confirmed (173).  
In conclusion, a great number of investigational drugs targeting many pathogenic mechanisms have 
been proposed for the treatment of endometriosis. However, the majority of these agents have been 
investigated only in experimental and preclinical models and more extensive researches are 
mandatory to address their efficacy and safety profiles in women.  
It is important to under light that current rodent models of endometriosis have some limitations: at 
first the endometriotic disease is experimentally induced, requiring excision of uterine horn 
endometrium and suturing of the implants into the peritoneal surface in the presence of E2 at high 
doses. In fact, this manipulation is required since rodents have an estrous cycle; it is rather 
controversial whether this procedure recapitulates accurately the pathophysiology of endometriosis. 
The only animal models that appear to be highly reproductive of human endometriosis are primate 
models in which a menstrual cycle is present. Anyway, these animals are rarely used in these pre-
clinical trials for high cost and ethical concerns. Secondly, the experimental endometriotic implants 
are often surgically induced only in peritoneum, and not in other localizations. It appears unlikely 
that investigational drugs may have the same efficacy in treating peritoneal lesions, OEs and, more 
importantly, large implants of DIE, which have an high content of fibromuscular tissue, and may 
have already been present for some years (171). Another important consideration is that the 
modification of size and number of implanted endometrium fragments are typically the main 
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outcome on studies on animal model whereas the more important outcome of human research for 
endometriosis today is generally symptomatic relief (174).  
In our opinion, only a minority of these tested drugs may be considered for future studies, as the 
safety profile of these agents is the turning point for their use in the treatment of a chronic benign 
disease. Thus, in the absence of solid clinical data deriving from large randomized controlled trials, 
the introduction of new targeted drugs for endometriosis is far to be realized. More clinical trials are 
mandatory before these therapies may be considered for the treatment of patients with 
endometriosis. 
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Tables 
 
Table 1. Investigated drugs for the treatment of endometriosis 
 
 Class Drugs Most advanced 
study 
Hormonal treatment GnRH antagonist Cetrorelix(1), elagolix(2) III(1,2) 
Aromatase 
inhibitors 
Anastrozole(1), letrozole(2) III(1,2) 
SERM Bezedoxifene(1), 
raloxifene(2) 
II(1,2) 
SPRM Mifepristone(1), 
anoprisnil(2) 
II(1,2) 
Anti-angiogenic drugs Anti-VEGF Bevacizumab(1) Animal model(1)
TKIs Sunitib(1), Sorafenib(2), 
Pazopanib(3) 
Animal model(1,2,3)
mTOR Rapamycin(1), 
Temsirolimus(2), 
Everolimus(3) 
Animal model(1,2,3) 
Dopamine 
agonists 
Cabergoline(1), 
quinagolide(2) 
 
II(1,2) 
Others TNP-470(1) Animal model(1) 
Anti-inflammatory COX-2 inhibitors Parecoxib(1), celecoxib(2) Animal model(1,2) 
Anti TNF-α Etanercept(1), infliximab(2), Animal model(1,3,4), 
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TNFRSF1A(3) and c5N(4) phase II(2) 
MAPK inhibitors SB203580(1), FR167653(2) Animal model(1,2) 
Immunomodulators NfKb inhibitors IkB protease inhibitor 
(TPCK)(1), BAY 11-
7085(2), urinary preparation 
of human chorionic 
gonadotropin A (hCG-
A)(3), 
pyrrolidinedithiocarbamate 
(PDTC)(4), costunolide(5), 
curcumin(6),  
Animal 
model(1,2,3,4,5,6), I-II(7) 
 Others DLBS1442(1), 
imiquimod(2), 
bentamapimod(3), V-endo(4) 
 
Animal model(1,2,3), I-
II(4) 
Antioxidants drugs Statins Endostatin(1), simvastatin(2), 
atorvastatin(3), 
rosuvastatin(4) 
Animal model(1,2,3,4,)
Antidiabetic 
drugs 
Metformin(1), ciglitazone(2), 
pioglitazione(3), 
rosiglitazone(4) 
Animal model(1,2,3,4) 
Vitamins Elocalcitol (Vit D) (1), 
retinoic acid (Vit A) 
Animal model(1,2)
Other 
antioxidants 
Omega-3 fatty acids(1), N-
acetylcysteine(2), α-lipoic 
Animal model(1,3), 
II(2) 
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Figure 1. The pathogenesis of endometriosis involved several factors. The improvement of the 
knownledge of principal pathways alterated in this benign chronic disease is leading to the 
development of new specific targeted drugs. 
